Publisher： Bentham Science Publishers
E-ISSN： 1875-533x|18|19|2867-2884
ISSN： 0929-8673
Source： Current Medicinal Chemistry, Vol.18, Iss.19, 2011-06, pp. : 2867-2884
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Casein kinase 2 (CK2) is a ubiquitous, highly pleiotropic and essential protein kinase whose abnormally high constitutive activity has been implicated in several human diseases. In the last decade, several ATP competitive inhibitors of CK2, characterized by an in vitro activity that ranges from micromolar to nanomolar, have been discovered. However, until now only one drug candidate has been entered in Phase I clinical trial as a potential anticancer drug. Why this constitutively active kinase is so undruggable? Can ATP competitive inhibitors be considered the most promising drug candidates for the near future?In this review, we would like to underline how targeting binding sites outside the conventional ATP-binding could represent a new promising strategy to inhibit CK2 activity and, consequently, bear a great potentiality in discovering new drug candidates.
Related content
Kinase CK2 Inhibition: An Update
Current Medicinal Chemistry, Vol. 20, Iss. 5, 2013-02 ,pp. :
Access to resources
Recommend
Protein Kinase CK2 in Human Diseases
Current Medicinal Chemistry, Vol. 15, Iss. 19, 2008-01 ,pp. :
ATP Site-Directed Inhibitors of Protein Kinase CK2: An Update
Current Topics in Medicinal Chemistry, Vol. 11, Iss. 11, 2011-06 ,pp. :